RapidAI Reveals Superiority Over Competition in LVO Detection – 33% More Cases Identified Than Leading Competitor, Alongside Numerous Abstracts at ISC 2025

DUEL study reveals RapidAI’s unmatched accuracy (98% sensitivity vs Viz.ai 74% sensitivity) in stroke detection, alongside additional transformative hemorrhagic validation data and 17 new studies

RapidAI Reveals Superiority Over Competition in LVO Detection – 33% More Cases Identified Than Leading Competitor, Alongside Numerous Abstracts at ISC 2025

RapidAI Media Contact:
Jessica Stebing
Group Manager, Marketing Communications
260.336.6202
stebing@rapidai.com

The numbers speak for themselves, RapidAI’s deep clinical AI is delivering results where competitors are falling short. New data from the largest head-to-head study to date proves RapidAI’s LVO detection outperforms Viz.ai by a staggering 33%, detecting far more stroke cases and reducing the risk of missed diagnoses.

These findings, along with 17 influential studies, will be showcased at the American Heart Association’s International Stroke Conference (ISC) in Los Angeles from February 5-7. Key highlights include landmark research in large vessel occlusion (LVO) and subdural hematoma (SDH) detection, reinforcing RapidAI’s dominance in AI-powered stroke care.

DUEL - Detection of LVO Using AI: Evaluating RapidAI versus Viz.ai in Detection of Large Vessel Occlusion on CT Angiography in a Large Consecutive Patient Series of 1,591 Code Strokes
Late-Breaking Science Poster: February 5, 7-7:30 p.m. PST

In the largest 1,591 patient head-to-head consecutive comparison to date, the DUEL study evaluated the performance of Rapid LVO versus Viz LVO software, exposing critical performance gaps in Viz.ai’s LVO detection software.

LVOs occur when a major artery in the brain becomes blocked, making timely and accurate detection crucial for patient outcomes. If left undiagnosed, LVOs can cause significant neurological damage, leading to long-term disability or death.

DUEL data demonstrate the superiority of Rapid LVO versus Viz LVO, notably:

• Rapid LVO detected 33% more LVO-positive cases than Viz LVO (98% versus 74%)
• Viz LVO failed to detect 26% of the LVO-positive cases
• Rapid LVO correctly identified 94% of LVO-negative cases compared to 91% for Viz LVO

“Trusting the accuracy of clinical AI tools is critically important, especially for time-sensitive conditions like stroke,” said Harmeet Sachdev, M.D., lead author and neurologist. “By comparing two leading AI-driven tools, we now have a clearer understanding of performance differences, including important distinctions in sensitivity and specificity. Our findings raise the concern about missing LVO detection, and causing potential delays in diagnosis and treatment in a substantial number of patients.”

Performance of RAPID SDH for detection of both Acute and Chronic Subdural Hematomas
Moderated Poster Tour: February 5, 6:10-6:15 p.m. PST

The accuracy of Rapid SDH was compared to gold-standard expert readers (n=313). SDH is a serious condition where blood collects between the skull and the surface of the brain, causing pressure that can lead to severe neurological damage or death. AI software has the potential to expedite SDH diagnosis and treatment, which can lead to faster intervention and improved patient outcomes.

Study results show Rapid SDH provides fast and accurate detection of both acute and chronic SDH on NCCT.

• Rapid SDH demonstrated a sensitivity of 92.4% and a specificity of 98.7% for the detection of SDH.
• The median processing time was approximately 45 seconds.

Additional clinical data highlighting the important role of RapidAI’s platform in expediting door-to-treatment times and supporting improved patient outcomes will also be shared at the conference. Check the ISC website or our Must-See Guide for more information.

“Clinicians need a deep clinical AI platform they can trust — one that delivers accuracy, speed, and reliability,” said David Stoffel, CBO of RapidAI. “That’s exactly what we’ve built. As the market leader in deep clinical AI, RapidAI is more than just an algorithm — it’s the foundation for high-performing neuroscience programs. Our rigorously validated, seamlessly integrated platform supports confident decision-making when it matters most. With the industry’s most advanced AI, we’re not just improving detection — we’re empowering hospitals to elevate stroke and hemorrhagic care and optimize workflows. And with the launch of Lumina 3D™ by RapidAI, this study confirms that our customers have invested in the right platform to deliver the best patient care possible.”

About RapidAI

RapidAI is the world leader in AI-driven medical imaging analysis and coordinated care. With the industry’s most validated clinical AI platform, we empower care teams to rapidly, precisely, and confidently manage life-threatening conditions. Trusted by thousands of hospitals in 100+ countries, RapidAI delivers the deepest level of clinical decision support on the market to help accelerate the time to treatment and enhance patient outcomes. We go beyond the algorithm to drive care team collaboration and efficiencies that expand access to life-saving interventions. At RapidAI, we establish new standards for care teams and the patients they treat.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250205284481/en/